Related Experiment Video
Updated: Mar 10, 2026
07:21
Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor
Published on: May 2, 2022
2.7K
Gastrointestinal stromal tumours (GISTs): A descriptive study on 29 cases
Lamine Hamzaoui1, Mouna Medhioub1, Mahdi Bouassida2
1Gastroenterology Department, Mohamed Tahar Maamouri Hospital, Nabeul, Tunisia; Faculty of Medicine of Tunis, University of Tunis El Manar, Tunisia.
Summary
Gastrointestinal stromal tumours (GISTs) are common. Surgical resection is the primary treatment, but imatinib did not improve survival in advanced cases.
Area of Science:
- Gastroenterology
- Surgical Oncology
- Medical Oncology
Background:
- Gastrointestinal stromal tumours (GISTs) are the most common mesenchymal neoplasms of the digestive tract.
- These tumours originate from interstitial cells of Cajal.
- Understanding GIST characteristics is crucial for effective management.
Purpose of the Study:
- To analyze the epidemiological, clinical, histological, and therapeutic features of GISTs.
- To provide insights into the management of GIST patients.
- To evaluate treatment outcomes in a Tunisian cohort.
Main Methods:
- Retrospective descriptive study of 29 GIST cases.
- Data collected from January 2005 to March 2012.
- Analysis included patient demographics, symptoms, tumor characteristics, and treatment modalities.
Main Results:
- Median age of patients was 63 years; common symptoms included abdominal pain and weight loss.
- Stomach and small intestine were the most frequent sites; median tumor size was 9.5cm.
- Surgical resection was performed in 72% of primary cases; imatinib was used in 24% of patients.
Conclusions:
- Surgical resection remains the cornerstone of GIST management.
- Imatinib treatment did not demonstrate improved overall survival in metastatic or inoperable GIST patients in this cohort.
- Further research into advanced GIST therapies is warranted.
